

## Oasmia's Nomination Committee revises its proposal for the AGM regarding Board of Directors

The Nomination Committee of Oasmia Pharmaceutical AB has been notified by Sven Rohmann of his new role as CEO of Immunicum AB. The Nomination Committee is of the view that the new role creates potential conflicts of interest, which could be adverse material to Oasmia. Due to this, the Nomination Committee has revised its proposal and Sven has notified that he is no longer available for re-election.

Pursuant to the revised proposal, the Nomination Committee proposes that the Board shall consist of four members without alternates, with re-election of Chairman of the Board Anders Härfstrand and re-election of Board members Hege Hellström, Birgit Stattin Norinder and Peter Zonabend. The Nomination Committee's proposal is otherwise unchanged in relation to the proposal presented on 10 August 2020, which is included in the notice of the Annual General Meeting.

The Annual General Meeting in Oasmia will be held on 9 September 2020 at the offices of the company, Vallongatan 1, 752 28 Uppsala. Further information about the Annual General Meeting is available on Oasmia's website, [www.oasmia.com](http://www.oasmia.com).

### For more information:

Francois Martelet, Chief Executive Officer Oasmia

Phone: +46 18-50 54 40

E-mail: [IR@oasmia.com](mailto:IR@oasmia.com)

### About Oasmia Pharmaceutical

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Oasmia produces novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on Oasmia's proprietary technology platform XR17. Oasmia has been successful in moving its first product candidate, Apealea® (paclitaxel micellar), through clinical development, and has received market authorization in the European Union and other territories. Oasmia is in the process of transitioning into the commercialization phase of the product Apealea and making the product accessible to patients via its partnership with Elevar and its existing operations and partnerships in its retained territories. The company's shares are traded on Nasdaq Stockholm (ticker: OASM). Visit [www.oasmia.com](http://www.oasmia.com) for further information.

### Attachments

---

[Oasmia's Nomination Committee revises its proposal for the AGM regarding Board of Directors](#)

---